vs
Side-by-side financial comparison of MediWound Ltd. (MDWD) and Regencell Bioscience Holdings Ltd (RGC). Click either name above to swap in a different company.
MediWound Ltd. is a biopharmaceutical company specializing in the research, development, production and commercialization of innovative products for burn care, chronic wound treatment and soft tissue repair. It operates mainly across North America, Europe and Asia, serving hospitals, healthcare providers and patients in the wound care segment.
Regencell Bioscience Holdings Ltd is a specialized bioscience enterprise focused on the research, development and commercialization of therapeutic products derived from traditional Chinese medicine. Its core pipeline targets neurodegenerative, immunological and infectious disease treatments, with primary operating markets across Greater China and other Asian regions.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q2 25 | $5.7M | — | ||
| Q2 24 | $5.1M | — | ||
| Q2 23 | $4.8M | — | ||
| Q2 22 | $4.7M | — |
| Q2 25 | $-13.3M | — | ||
| Q2 24 | $-6.3M | — | ||
| Q2 23 | $916.0K | — | ||
| Q2 22 | $-4.4M | — |
| Q2 25 | 23.5% | — | ||
| Q2 24 | 8.8% | — | ||
| Q2 23 | 23.8% | — | ||
| Q2 22 | 23.8% | — |
| Q2 25 | -100.1% | — | ||
| Q2 24 | -88.6% | — | ||
| Q2 23 | -84.0% | — | ||
| Q2 22 | -78.7% | — |
| Q2 25 | -233.3% | — | ||
| Q2 24 | -124.5% | — | ||
| Q2 23 | 19.2% | — | ||
| Q2 22 | -93.3% | — |
| Q2 25 | $-1.23 | — | ||
| Q2 24 | $-0.68 | — | ||
| Q2 23 | $0.10 | — | ||
| Q2 22 | $-0.92 | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
